이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

강직성 척추염 및 비방사선학적 축방향 척추관절염을 포함한 활동성 축방향 척추관절염 환자에서 비메키주맙의 장기 안전성, 내약성 및 효능을 평가하기 위한 연구 (BE MOVING)

2026년 11월 2일 업데이트: UCB Biopharma SRL

활동성 축방향 척추관절염, 강직성 척추염 및 비방사선 촬영 축방향 척추관절염이 있는 연구 참가자의 치료에서 비메키주맙의 장기 안전성, 내약성 및 효능을 평가하기 위한 다기관 공개 확장 연구

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

연구 개요

연구 유형

중재적

등록 (실제)

508

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Amsterdam, 네덜란드
        • As0014 40034
      • Berlin, 독일
        • As0014 40025
      • Hamburg, 독일
        • As0014 40029
      • Hanover, 독일
        • As0014 40024
      • Herne, 독일
        • As0014 40027
      • Leipzig, 독일
        • As0014 40078
      • Ratingen, 독일
        • As0014 40026
    • Arizona
      • Glendale, Arizona, 미국, 85306
        • As0014 50062
      • Phoenix, Arizona, 미국, 85032
        • As0014 50052
    • California
      • Upland, California, 미국, 91786
        • As0014 50060
    • Florida
      • Ormond Beach, Florida, 미국, 32174
        • As0014 50059
      • Sarasota, Florida, 미국, 34239
        • As0014 50056
    • Maryland
      • Hagerstown, Maryland, 미국, 21740
        • As0014 50015
    • Missouri
      • St Louis, Missouri, 미국, 63141
        • As0014 50016
    • Oregon
      • Portland, Oregon, 미국, 97239
        • As0014 50055
    • Pennsylvania
      • Duncansville, Pennsylvania, 미국, 16635
        • As0014 50020
    • Texas
      • Dallas, Texas, 미국, 75231
        • As0014 50057
      • Brussels, 벨기에
        • As0014 40004
      • Genk, 벨기에
        • As0014 40003
      • Ghent, 벨기에
        • As0014 40001
      • Plovdiv, 불가리아
        • As0014 40006
      • Plovdiv, 불가리아
        • As0014 40007
      • Sofia, 불가리아
        • As0014 40005
      • Sofia, 불가리아
        • As0014 40008
      • A Coruña, 스페인
        • As0014 40045
      • Córdoba, 스페인
        • As0014 40046
      • Santiago de Compostela, 스페인
        • As0014 40048
      • Seville, 스페인
        • As0014 40049
      • Edinburgh, 영국
        • As0014 40057
      • Leeds, 영국
        • As0014 40056
      • Norwich, 영국
        • As0014 40055
      • Bunkyō City, 일본
        • As0014 20035
      • Chūōku, 일본
        • As0014 20030
      • Iruma-gun, 일본
        • As0014 20039
      • Kawachi-Nagano, 일본
        • As0014 20036
      • Kita-gun, 일본
        • As0014 20045
      • Kitakyushu, 일본
        • As0014 20065
      • Osaka, 일본
        • As0014 20037
      • Saga, 일본
        • As0014 20084
      • Saitama, 일본
        • As0014 20048
      • Sapporo, 일본
        • As0014 20031
      • Suita, 일본
        • As0014 20032
      • Beijing, 중국
        • As0014 20040
      • Chengdu, 중국
        • As0014 20021
      • Guangzhou, 중국
        • As0014 20019
      • Hefei, 중국
        • As0014 20034
      • Nanjing, 중국
        • As0014 20024
      • Shanghai, 중국
        • As0014 20018
      • Shanghai, 중국
        • As0014 20020
      • Shanghai, 중국
        • As0014 20026
      • Wenzhou, 중국
        • As0014 20025
      • Brno, 체코
        • As0014 40011
      • Pardubice, 체코
        • As0014 40009
      • Prague, 체코
        • As0014 40013
      • Prague, 체코
        • As0014 40014
      • Prague, 체코
        • As0014 40015
      • Prague, 체코
        • As0014 40016
      • Uherské Hradiště, 체코
        • As0014 40010
      • Zlín, 체코
        • As0014 40012
      • Ankara, 터키 (Türkiye)
        • As0014 40052
      • Ankara, 터키 (Türkiye)
        • As0014 40053
      • Istanbul, 터키 (Türkiye)
        • As0014 40050
      • Elblag, 폴란드
        • As0014 40038
      • Krakow, 폴란드
        • As0014 40042
      • Lublin, 폴란드
        • As0014 40037
      • Poznan, 폴란드
        • As0014 40044
      • Torun, 폴란드
        • As0014 40040
      • Warsaw, 폴란드
        • As0014 40041
      • Wroclaw, 폴란드
        • As0014 40039
      • Wroclaw, 폴란드
        • As0014 40043
      • Boulogne-Billancourt, 프랑스
        • As0014 40018
      • Limoges, 프랑스
        • As0014 40022
      • Debrecen, 헝가리
        • As0014 40032
      • Szeged, 헝가리
        • As0014 40031
      • Székesfehérvár, 헝가리
        • As0014 40033

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
  • In the opinion of the Investigator, the study participant is expected to benefit from participation in this extension study
  • Study participant completed AS0010 (NCT03928704) or AS0011 (NCT03928743)

Exclusion Criteria:

  • Female study participants who plan to become pregnant during the study or within 20 weeks following final dose of Investigational Medicinal Product (IMP). Male study participants who are planning a partner pregnancy during the study or within 20 weeks following the final dose
  • Study participants who meet any withdrawal criteria in AS0010 or AS0011. For any study participant with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder study, the Medical Monitor must be consulted prior to the study participant's entry into AS0014
  • Study participant has a positive or indeterminate interferon gamma release assay (IGRA) in AS0010 or AS0011, unless appropriately evaluated and treated

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Bimekizumab

Subjects will receive bimekizumab throughout the Treatment Period.

Subjects will receive bimekizumab at prespecified time-points.

다른 이름들:
  • UCB4940
  • BKZ

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
기간: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
Percentage of participants with serious adverse events (SAEs) during the study
기간: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires in patient hospitalisation or prolongation of existing hospitalisation
  • Is a congenital anomaly or birth defect
  • Is an infection that requires treatment with parenteral antibiotics
  • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study
기간: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

2차 결과 측정

결과 측정
측정값 설명
기간
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 28
기간: Week 28

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))-
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 concerning morning stiffness intensity and duration)
Week 28
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 52
기간: Week 52

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 52
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 112
기간: Week 112

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 112
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 28
기간: Week 28

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 28
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 52
기간: Week 52

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 52
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 112
기간: Week 112

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 112
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 28
기간: Week 28

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS40 domains.

Week 28
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 52
기간: Week 52

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

Week 52
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 112
기간: Week 112

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

Week 112
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 28
기간: Week 28

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

Week 28
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 52
기간: Week 52

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

Week 52
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 112
기간: Week 112

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.+ 1)

Week 112
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 28
기간: Week 28

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS40 domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 28
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 52
기간: Week 52

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 52
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 112
기간: Week 112

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 112
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 28
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 52
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 112
기간: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: UCB Cares, 001 844 599 2273 (UCB)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 6월 16일

기본 완료 (실제)

2026년 8월 9일

연구 완료 (실제)

2026년 8월 9일

연구 등록 날짜

최초 제출

2020년 6월 15일

QC 기준을 충족하는 최초 제출

2020년 6월 15일

처음 게시됨 (실제)

2020년 6월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • AS0014
  • 2019-004163-47 (EudraCT 번호)
  • 2023-506527-28 (레지스트리 식별자: EU Clinical Trials)
  • U1111-1304-6865 (기타 식별자: World Health Organization (WHO))
  • 2023 (미국 NIH 보조금/계약)
  • 2019 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD 공유 기간

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD 공유 액세스 기준

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다